Latest revenue
$2.0M
as of 2025-09-30
Latest net income
$48.4M
as of 2025-09-30
Net margin
2419.8%
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $163.3M
- Enterprise value
- $163.3M
- P/E (trailing)
- 2.5×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 6.3%
- 52-wk high
- $5.01
- 52-wk low
- $1.98
- Beta
- —
- Shares out
- 40.9M
5-year trend
What this company does
ITEM 1. BUSINESS. Description of Business We are a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. In addition, we allocate capital to strategic investments in healthcare and life sciences companies that we believe complement our long-term business objectives and technology focus. We have developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. The formulation is not intended to modify the proteins chemically or biologically, and the dosage form is…
AI summary unavailable — showing raw filing excerpt
Generated from ORMP's filing dated 2026-03-26
Key risks
ITEM 1A. RISK FACTORS. An investment in our securities involves a high degree of risk. You should consider carefully the following information about these risks, together with the other information contained in this Annual Report on Form 10-K before making an investment decision. Our business, prospects, financial condition and results of operations may be materially and adversely affected as a result of any of the following risks. The value of our securities could decline as a result of any of these risks. You could lose all or part of your investment in our securities. Some of the statements in this “Item 1A. Risk Factors” are forward-looking statements. The following risk factors are not…
AI summary unavailable — showing raw filing excerpt
Generated from ORMP's filing dated 2026-03-26
Profitability
Gross margin
0.7%
Operating margin
-754.4%
35.9%Net margin
3202.5%
676.7%Return on equity
32.1%
345.5%Return on assets
633.0%
5245.1%Leverage
Debt / equity
-0.95×
1640.6%Debt / assets
-1873.9%
32384.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $-4.0M | — | $17.7M | +184.1% | — |
Q3 2025 2025-09-30 | $2.0M | — | $48.4M | +645.5% | 2419.8% |
Q2 2025 2025-06-30 | $2.0M | — | $5.6M | -38.7% | 282.3% |
Q1 2025 2025-03-31 | $2.0M | — | $-7.6M | -597.5% | -382.1% |
Q4 2024 2024-12-31 | — | — | $-21.0M | — | — |
Q3 2024 2024-09-30 | — | — | $-8.9M | -175.3% | — |
Q2 2024 2024-06-30 | — | — | $9.2M | +871.5% | — |
Q1 2024 2024-03-31 | — | — | $1.5M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ORMP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ORMP
Institutional value
$15.4M
Total shares held
4.5M
Distinct holders
31
-24 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BML Capital Management, LLC | 3.2M | $10.8M | +0 (+0.0%) | No change |
| 2 | Rathbones Group PLC | 233.0K | $792.3K | -233.0K (-50.0%) | Trimmed |
| 3 | DIMENSIONAL FUND ADVISORS LP | 158.2K | $537.7K | +7.7K (+5.1%) | Added |
| 4 | WELLS FARGO & COMPANY/MN | 157.6K | $535.8K | +27.0K (+20.7%) | Added |
| 5 | RITHOLTZ WEALTH MANAGEMENT | 155.5K | $528.6K | — | New |
| 6 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 116.4K | $395.6K | — | New |
| 7 | Hillsdale Investment Management Inc. | 97.3K | $330.8K | — | New |
| 8 | BlackRock, Inc. | 92.2K | $313.5K | +2.0K (+2.2%) | Added |
| 9 | JANE STREET GROUP, LLC | 52.5K | $178.6K | -25.7K (-32.9%) | Trimmed |
| 10 | Hudson Bay Capital Management LP | 51.7K | $175.7K | — | New |
| 11 | Connor, Clark & Lunn Investment Management Ltd. | 50.2K | $170.7K | +6.5K (+14.8%) | Added |
| 12 | BAILARD, INC. | 32.5K | $110.4K | — | New |
| 13 | Catalyst Funds Management Pty Ltd | 23.5K | $79.9K | — | New |
| 14 | PNC Financial Services Group, Inc. | 21.2K | $72.1K | +0 (+0.0%) | No change |
| 15 | Sage Capital Management, LLC | 18.0K | $61.1K | +1.2K (+7.3%) | Added |
| 16 | Kathmere Capital Management, LLC | 15.1K | $51.2K | — | New |
| 17 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 13.5K | $46.2K | -4.8K (-26.2%) | Trimmed |
| 18 | UBS Group AG | 11.7K | $39.7K | +9.1K (+353.1%) | Added |
| 19 | AXQ CAPITAL, LP | 11.3K | $38.5K | — | New |
| 20 | Glass Jacobson Investment Advisors llc | 10.5K | $35.8K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ORMP's latest filing finishes processing.